Principal Financial Group Inc. Grows Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Principal Financial Group Inc. raised its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 4.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 238,356 shares of the company's stock after acquiring an additional 9,267 shares during the quarter. Principal Financial Group Inc. owned approximately 0.51% of Omnicell worth $10,612,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. New York State Teachers Retirement System boosted its stake in shares of Omnicell by 2.4% during the fourth quarter. New York State Teachers Retirement System now owns 61,974 shares of the company's stock valued at $2,759,000 after acquiring an additional 1,432 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Omnicell in the fourth quarter valued at $297,000. Van ECK Associates Corp boosted its holdings in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares during the last quarter. Shaker Investments LLC OH bought a new stake in shares of Omnicell in the fourth quarter worth $550,000. Finally, Empowered Funds LLC bought a new position in shares of Omnicell during the fourth quarter worth about $388,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America reduced their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. StockNews.com lowered shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. Wells Fargo & Company cut their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Benchmark reissued a "buy" rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. lifted their target price on Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $52.33.

Remove Ads

Omnicell Stock Down 0.9 %

NASDAQ OMCL traded down $0.34 during trading on Tuesday, hitting $37.39. The stock had a trading volume of 316,406 shares, compared to its average volume of 491,300. The company's 50-day moving average price is $42.26 and its two-hundred day moving average price is $43.79. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market capitalization of $1.73 billion, a PE ratio of 138.63, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Insider Activity

In other news, Director Mark W. Parrish sold 12,000 shares of the firm's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 2.64% of the company's stock.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.